

Strand Life Sciences announces launch of prenatal genomic diagnostics portfolio

24 April 2024 | News

Advanced tests based on a genomic analysis pipeline specifically developed and validated on Indian samples and conditions



Bengaluru-based Strand Life Sciences has announced the launch of its prenatal screening and diagnostics portfolio with two breakthrough developments- CNSeq (sequencing based identification of aneuploidies and copy number variations) and MaatriSeq (Non-Invasive Prenatal Screening).

CNSeq brings the latest Next Generation Sequencing technology to an important prenatal test marking a significant leap forward in prenatal diagnostics. Leveraging proprietary software, CNSeq delivers unmatched precision in identifying Copy Number Variations (CNVs), outperforming traditional cytogenetic and molecular techniques.

On the other hand, MaatriSeq is the first Non-Invasive Prenatal Screening (NIPS) solution validated on the latest high-throughput Illumina NovaSeq X Plus sequencing platform.

This breakthrough offers a highly accurate and cost-effective solution, accessible to a wider community in India. These innovations underscore the company's commitment to innovate in genetic diagnostics and reduce the burden of rare diseases in India.

"With these innovations in advanced genetic technologies, Strand wants to contribute to the efforts by the Indian Government in reducing the burden of rare diseases in India," said Ramesh Hariharan, CEO and Co-founder of Strand Life Sciences.